尼可地尔对缺血性心肌病患者心功能及预后的影响

发布时间：2018-04-01 08:31

本文选题：尼可地尔　切入点：缺血性心肌病　出处：《中国地方病防治杂志》2017年01期

【摘要】：目的探究缺血性心肌病患者采用尼可地尔治疗对心功能与预后的影响。方法选取本院2014年3月~2015年6月收治的132例缺血性心肌病患者,并抽签分为两组,两组都接受常规治疗,随后,对照组加用单硝酸异山梨酯片治疗,观察组加用尼可地尔治疗,并对两组患者的心功能、预后情况进行对比。结果经过半年的治疗后,两组患者脑钠素与6分步行距离都有改善,且观察组改善程度优于对照组(P0.05);经过半年的治疗后,两组患者的LVEF、LVEDVI、LVESVI以及E/A都有改善,且观察组LVEDVI、LVESVI以及E/A的改善程度明显优于对照组(P0.05);观察组患者心脏不良事件发生率低于对照组(3.04%VS 12.12%),(P0.05)。结论缺血性心肌病患者采用尼可地尔治疗,可使患者的心功能充分改善,使心脏不良事件发生率有效降低,在临床上具有较高的推广价值。
[Abstract]:Objective to investigate the effect of nicorandil on cardiac function and prognosis in patients with ischemic cardiomyopathy. Methods 132 patients with ischemic cardiomyopathy from March 2014 to June 2015 were selected and divided into two groups. Then, the control group was treated with isosorbide mononitrate and the observation group with nicorandil. The cardiac function and prognosis of the two groups were compared. The distance between brain natriuretic peptide (BNP) and walking distance of 6 minutes was improved in both groups, and the improvement in the observation group was better than that in the control group (P 0.05). After half a year of treatment, the LVEFV, LVEDVI, LVESVI and E / A were improved in both groups. The improvement of LVEDVI LVESVI and E / A in the observation group was significantly better than that in the control group (P 0.05), and the incidence of adverse cardiac events in the observation group was lower than that in the control group (3.04 vs 12.12). Conclusion the patients with ischemic cardiomyopathy can be treated with nicorandil to improve their cardiac function. So that the incidence of adverse cardiac events can be effectively reduced, and has a high value in clinical promotion.
【作者单位】：黑龙江省齐齐哈尔医学院附属第三医院;
【分类号】：R542.2

【参考文献】